<DOC>
	<DOCNO>NCT02857660</DOCNO>
	<brief_summary>The aim study determine effect 16 week Whole Body-Electromyostimulation ( WB-EMS ) and/or protein supplementation Sarcopenic Obesity ( SO ) community dwell male subject 70+ SO . 108 eligible men randomly assign either ( 1 ) WB-EMS Protein ( 2 ) Protein ( 3 ) sedentary control group . WB-EMS apply 1,5 x 20 min per week ( i.e . 3 session two week ) bipolar current , 85 Hz intermit mode ( 4 - 4 rest ) . Protein supplementation adjust dietary intake order reach total protein intake 1,5 - 1,7g/kg body-mass/d . Primary study endpoint Sarcopenia Z-Score</brief_summary>
	<brief_title>Effect Whole Body Electromyostimulation and/or Protein Supplementation Sarcopenic Obesity 70+</brief_title>
	<detailed_description>The aim study evaluate effect Whole-Body Electromyostimulation ( WB-EMS ) additional protein supplementation Sarcopenic Obesity parameter independently live men 70 year old sarcopenic obesity . The randomized control study compare three group 36 subject : ( 1 ) WB-EMS additional protein supplementation , ( 2 ) protein-only ( 3 ) passive control group , period 16 week WB-EMS -training . Group ( 1 ) conduct 1.5-times/week 20 minute-sessions WB-EMS additional protein , group ( 2 ) limit protein supplementation ( ) group ( 3 ) constrain maintain habitual living behavior physical activity . Based individual nutrition analysis protein intake adjust 1.5-1.7 g/kg/ bodymass/d . All group supplement maximum 800 IE Vitamin D. Primary study endpoint change Sarcopenia Z-Score skeletal muscle mass assess via bio-impedance analysis ( BIA ) . Secondary study endpoint change Obesity ( i.e . body-fat assess via BIA ) , cardiometabolic risk ( i.e . Metabolic Syndrome Z-Score ) , strength parameter evaluate via Dr. Wolff BackCheck Physiomed LegPress , quality life ( SF-12 ) functional disability ( late life physical disability index ) .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<criteria>community dwelling , independent live men Sarcopenia Obesity ( body fat &gt; =25 % ) exclusion criterion WBEMSapplication ( e.g . cardiac pacemaker ) diseases/medication affect study endpoint ( e.g . Glucocorticoids &gt; 5mg/d ) absence 2 week study period</criteria>
	<gender>Male</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Sarcopenia</keyword>
	<keyword>Obesity</keyword>
	<keyword>Whole-Body Electromyostimulation</keyword>
	<keyword>Protein Supplementation</keyword>
	<keyword>community dwell men</keyword>
</DOC>